Zyla life sciences (EGLT)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Operating activities:
Net (loss) income

-46,640

-95,454

-69,359

-90,632

-57,933

-

-

-

Net loss

-

-

-

-

-

-43,214

-20,207

-5,398

Adjustment to reconcile net (loss) income to net cash (used in) provided by operating activities:
Depreciation and amortization

13,576

4,193

5,062

4,118

3,014

641

483

404

Loss on disposal of property and equipment

-33

-

-

-

-

-

-

-

Non-cash impairment of property and equipment

-

6,886

-

-

-

-

-

-

Change in fair value of warrant and derivative liability

-

12,292

2,546

644

260

-

-

-

Stock-based compensation expense

2,237

3,973

5,918

6,323

5,199

8,518

-

-

Non-cash interest and amortization of debt discount

6,111

38,307

5,070

5,911

3,957

-

-

-

Noncash interest and amortization of debt discount

-

-

-

-

-

6,987

8,431

-

Accretion of discount on marketable securities

-3

-209

-24

607

829

-

-

-

Deferred income taxes

-

-1

-

-

-

-

-

-

Change in right of use assets

-818

-

-

-

-

-

-

-

Change in fair value of contingent consideration

4,983

-

-

-

-

-

-

-

Deferred income taxes

-

-

-

-1,061

-718

6

22

-

Conversion of debt and interest into preferred stock

-

-

-

-

-

-

-

5,949

Gain on extinguishment of debt

-

-

13,221

-800

-

-

-657

1,424

Changes in assets and liabilities:
Related party receivable

-

-

-

-57

-563

744

-34

-1

Accounts receivable

21,556

4,257

3,012

813

295

-

-

-96

Inventory

-24,789

-429

1,525

-137

-1,571

-

-

-

Prepaid expenses

159

46

132

1,243

631

540

-350

2

Other receivables

685

-3

-219

-28

144

883

-99

310

Deposits and other assets

1,467

666

375

-1,481

2,050

-

7

-

Accounts payable

4,416

-1,600

7,597

-2,945

1,147

3,268

-378

72

Accrued expenses

3,582

6,104

-2,132

10,553

5,123

1,412

706

169

Deferred revenue

-

-

3,475

-

-

-

-

-

Deferred revenue

-

-

-

-6,153

1,485

-557

10,000

-508

Other current liabilities

-45

-

-

-187

116

32

34

16

Other liabilities

682

-184

-

-

-

-

-

-

Other liabilities

-

-

-179

796

121

-

-

-

Net cash provided by (used in) operating activities

-10,964

-54,814

-65,164

-72,867

-38,906

-

-

-

Investing activities:
Net cash used in operating activities

-

-

-

-

-

-25,074

-433

-5,460

Payments for purchase of property and equipment

40

9

88

7,237

2,747

2,889

1,791

314

Proceeds from disposal of property and equipment

13

-

-

-

-

-

-

-

Increase in restricted cash

-

-

-

-

1,223

-

-

-

Deposits for purchases of property and equipment

-

-

-

-

-

854

-

-

Purchases of investments

-

23,465

101,338

59,545

110,216

-

-

-

Sales of investments

2,497

4,509

12,195

14,370

3,400

-

-

-

Maturity of investments

2,500

74,174

71,647

101,277

6,799

-

-

-

Purchase of SPRIX Nasal Spray

-

-

-

-

8,128

-

-

-

License of OXAYDO

-

-

-

-

7,672

-

-

-

Net cash (used in) provided by investing activities

4,970

55,209

-17,584

48,865

-119,787

-

-

-

Financing activities:
Net proceeds from issuance of common stock

-

-

32,888

272

80,896

-

-

-

Proceeds from IPO, net of costs

-

-

-

-

-

53,032

-

-

Net proceeds from issuance of common stock

-

5,228

-

-

-

13,950

-

-

Payments of contingent consideration

1,883

-

-

-

-

-

-

-

Payments on borrowings

-

895

-

15,856

-

-

-

-

Payments of tax withholdings on restricted stock

138

-

-

-

-

-

-

-

Proceeds from credit agreement

3,770

-

-

-

-

-

-

-

Net proceeds from debt and royalty rights

-

-

38,304

37,231

71,397

-

-

-

Net cash (used in) provided by investing activities

-

-

-

-

-

-3,743

-1,791

-314

Exchange of convertible notes

-

-

-1,532

-

-

-

15,000

-

Royalty payments in connection with the 13% Notes

835

421

307

-

-

-

-

-

Net cash (used in) provided by financing activities

914

3,912

69,353

21,647

152,293

-

-

-

Effect of foreign currency translation on cash and cash equivalents

-2

-74

530

45

327

-

-

-

Net increase (decrease) cash, cash equivalents and restricted cash

-5,082

4,233

-12,865

-

-

-

-

-

Payment of deferred financing fees

-

-

-

-

-

-

1,443

-

Proceeds from the sale of Series B preferred stock

-

-

-

-

-

-

-

8,218

Net cash provided by financing activities

-

-

-

-

-

66,982

13,557

8,218

Effect of foreign currency translation on cash and cash equivalents

-

-

-

-

-

-1,127

963

-92

Net decrease in cash and cash equivalents

-

-

-

-2,310

-6,073

-

-

-

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

37,038

12,296

2,352

Supplemental disclosures of cash flow information:
Conversion of convertible preferred stock

-

-

-

-

-

14,957

-

-

Gain (loss) on extinguishment of debt

-

-

13,221

-800

-

-

-657

1,424

Beneficial conversion features

-

-

-

-

-

-

5,000

-

Cash interest payments

4,782

11,896

12,817

4,712

3,461

-

-

-

Non-cash purchases of property and equipment

-

-

-

-

2,084

-

62

348

Non-cash financing activities:
Fair value of warrants issued in connection with debt and common stock

-

-

9,667

-

329

-

-

-

Reclassification to additional paid-in capital of derivative liability

-

12,496

9,030

-

-

-

-

-

Fair value of warrants issued in connection with common stock

-

-

3,640

-

-

-

-

-

Conversion of related party convertible debt

-

-

-

-

-

24,713

-

-